Stock Scorer

Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. reported revenue of 0 USD for the quarter ending 31 December 2025.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q4 '25 · ending 31 December 2025 0 —
Operating Income Q2 '26 · ending 30 June 2026 -29.3M —
Net Income Q2 '26 · ending 30 June 2026 -26.2M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -16M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -16.1M —
Shares Outstanding Q2 '26 · ending 30 June 2026 76.3M +22.1%
EPS Q2 '26 · ending 30 June 2026 -1.21 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 0-84.8M-74.9M-60.4M
20242024-12-31 80M-21.9M-9.7M-2.5M
20232023-12-31 2.8M-110.7M-97.3M-91.5M
20222022-12-31 6.3M-112.6M-109.9M-99M
20212021-12-31 19.2M-81.1M-80.8M-80.2M
20202020-12-31 8.8M-71.6M-70.8M-55M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q4 '252025-12-310
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-310
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-3080M
Q1 '242024-03-310
Q4 '232023-12-31871K
Q3 '232023-09-30759K
Q2 '232023-06-30880K
Q1 '232023-03-31295K
Q4 '222022-12-31685K
Q3 '222022-09-301.2M
Q2 '222022-06-301.9M
Q1 '222022-03-312.6M
Q4 '212021-12-315.1M
Q3 '212021-09-304.9M
Q2 '212021-06-304.4M
Q1 '212021-03-314.8M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-29.3M
Q1 '262026-03-31-22.2M
Q4 '252025-12-31-22.7M
Q3 '252025-09-30-21.9M
Q2 '252025-06-30-19.8M
Q1 '252025-03-31-20.4M
Q4 '242024-12-31-19.4M
Q3 '242024-09-30-25.1M
Q2 '242024-06-3052.5M
Q1 '242024-03-31-29.8M
Q4 '232023-12-31-28M
Q3 '232023-09-30-27.4M
Q2 '232023-06-30-27.3M
Q1 '232023-03-31-27.9M
Q4 '222022-12-31-28M
Q3 '222022-09-30-24.4M
Q2 '222022-06-30-34.2M
Q1 '222022-03-31-26M
Q4 '212021-12-31-23.6M
Q3 '212021-09-30-20.8M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-26.2M
Q1 '262026-03-31-18.9M
Q4 '252025-12-31-20.3M
Q3 '252025-09-30-19.6M
Q2 '252025-06-30-17.3M
Q1 '252025-03-31-17.7M
Q4 '242024-12-31-16.6M
Q3 '242024-09-30-21.7M
Q2 '242024-06-3055.4M
Q1 '242024-03-31-26.9M
Q4 '232023-12-31-24.8M
Q3 '232023-09-30-24M
Q2 '232023-06-30-23.8M
Q1 '232023-03-31-24.8M
Q4 '222022-12-31-26.1M
Q3 '222022-09-30-23.7M
Q2 '222022-06-30-34.1M
Q1 '222022-03-31-25.9M
Q4 '212021-12-31-23.5M
Q3 '212021-09-30-20.7M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-16M
Q1 '262026-03-31-18.8M
Q4 '252025-12-31-16.8M
Q3 '252025-09-30-14.2M
Q2 '252025-06-30-13.8M
Q1 '252025-03-31-15.3M
Q4 '242024-12-31-16.8M
Q3 '242024-09-30-19.1M
Q2 '242024-06-3058.9M
Q1 '242024-03-31-25.3M
Q4 '232023-12-31-23.2M
Q3 '232023-09-30-22.9M
Q2 '232023-06-30-20.8M
Q1 '232023-03-31-24.1M
Q4 '222022-12-31-19.7M
Q3 '222022-09-30-27.9M
Q2 '222022-06-30-27.4M
Q1 '222022-03-31-22.1M
Q4 '212021-12-31-21.9M
Q3 '212021-09-30-22.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-16.1M
Q1 '262026-03-31-18.8M
Q4 '252025-12-31-17M
Q3 '252025-09-30-14.3M
Q2 '252025-06-30-13.9M
Q1 '252025-03-31-15.3M
Q4 '242024-12-31-17M
Q3 '242024-09-30-19.1M
Q2 '242024-06-3058.9M
Q1 '242024-03-31-25.3M
Q4 '232023-12-31-23.2M
Q3 '232023-09-30-23M
Q2 '232023-06-30-21M
Q1 '232023-03-31-24.3M
Q4 '222022-12-31-19.8M
Q3 '222022-09-30-28.2M
Q2 '222022-06-30-28.7M
Q1 '222022-03-31-22.4M
Q4 '212021-12-31-22.4M
Q3 '212021-09-30-22.9M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3076.3M
Q1 '262026-03-3176.2M
Q3 '252025-09-3062.6M
Q2 '252025-06-3062.5M
Q1 '252025-03-3162.5M
Q3 '242024-09-3062.4M
Q2 '242024-06-3063.6M
Q1 '242024-03-3162M
Q3 '232023-09-3061.8M
Q2 '232023-06-3061.8M
Q1 '232023-03-3159.7K
Q3 '222022-09-3046.2K
Q2 '222022-06-3040.9K
Q1 '222022-03-3140.6K
Q3 '212021-09-3036.6K
Q2 '212021-06-3032.6K

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-1.21
Q1 '262026-03-31-1.15
Q4 '252025-12-31-1.18
Q3 '252025-09-30-1.12
Q2 '252025-06-30-1.16
Q1 '252025-03-31-0.01
Q4 '242024-12-31-0.16
Q3 '242024-09-30-0.31
Q2 '242024-06-30-0.35
Q1 '242024-03-31-1.60
Q1 '212021-03-31-2.53
Q4 '202020-12-31-2.80
Q3 '202020-09-3024.17
Q2 '202020-06-3023.90
Q1 '202020-03-3115.35
Q4 '192019-12-31-8.13
Q3 '192019-09-30-42.33
Q2 '192019-06-30-49.44
Q1 '192019-03-31-47.73
Q4 '182018-12-31-31.14